ストックスクリーナーアプリを入手
7.92
9.70%
0.70
アフターアワーズ：
7.88
-0.04
-0.51%
前日終値:
$7.22
開ける：
$7.28
24時間の取引高:
19.03M
Relative Volume:
0.83
時価総額：
$8.30B
収益：
$113.29M
当期純損益:
$-351.47M
株価収益率:
-20.32
EPS:
-0.3898
ネットキャッシュフロー:
$-309.19M
1週間 パフォーマンス:
+2.06%
1か月 パフォーマンス:
+6.45%
6か月 パフォーマンス:
+271.83%
1年 パフォーマンス:
+213.04%
1日の値動き範囲:
$7.27
$8.03
1週間の範囲:
$7.15
$8.64
52週間の値動き範囲:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.92 | 7.56B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX - GlobeNewswire Inc.
IBRX Stock Jumps As ANKTIVA Bladder Cancer Story Strengthens - StocksToTrade
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - Caledonian Record
IBRX Stock Climbs As ANKTIVA Franchise Momentum Builds - timothysykes.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. LawsuitIBRX - PR Newswire
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Eagle-Tribune
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman - PR Newswire
Virtus Investment Advisers, LLC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ImmunityBio, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
IBRX stock jumps overnight after major FDA review win for Anktiva in bladder cancer - MSN
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - TMX Newsfile
symbol__ Stock Quote Price and Forecast - CNN
Press releases provided by CNW - Techaeris
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc.IBRX - lincolnjournal.com
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar - GlobeNewswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - Toronto Star
IBRX says ANKTIVA delivers up to $314K cost advantage over J&J's TAR-200 — everything to know about ImmunityBio’s findings - MSN
ImmunityBio presents UK bladder cancer patient survey data By Investing.com - Investing.com South Africa
Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with N - pharmiweb.com
IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s Findings - Yahoo Finance
ImmunityBio reports cost analysis for bladder cancer treatment - Investing.com
ImmunityBio presents UK bladder cancer patient survey data - Investing.com
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation - Business Wire
TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) - GlobeNewswire
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRGRD Law – Company AnnouncementFT.com - Financial Times
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - TMX Newsfile
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX Stock Drops As FDA Warning Triggers Class Actions - timothysykes.com
Tamar Securities Financial PortalImmunityBio, Inc.Common Stock (Nasdaq:IBRX) Stock Quote - FinancialContent
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ... - Caledonian Record
IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS - Morningstar
ImmunityBio stock (US45258J1025): FDA accepts ANKTIVA bladder cancer filing and sets 2027 PDUFA date - AD HOC NEWS
IBRX 6-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - marketscreener.com
Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price Cooldown - Yahoo Finance
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):